UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
| |
|
|
| (Check One): |
|
¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR |
| |
|
| |
|
For Period Ended: September 30, 2026 |
| |
|
| |
|
¨ Transition Report on Form 10-K |
| |
|
¨ Transition Report on Form 20-F |
| |
|
¨ Transition Report on Form 11-K |
| |
|
¨ Transition Report on Form 10-Q |
| |
|
| |
|
For the Transition Period Ended: |
|
Read Instruction (on back page) Before Preparing
Form. Please Print or Type.
Nothing in this form shall be construed to imply
that the Commission has verified any information contained herein. |
If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:
PART I-REGISTRANT INFORMATION
International Stem Cell Corporation
Full name of Registrant
N/A
Former name if Applicable
9745 Businesspark Ave
Address of Principal Executive Office (Street and
number)
San Diego, California 92131
City, State and Zip Code
PART II-RULE 12b-25 (b) AND (c)
If the subject report could not be filed without
unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box
if appropriate.)
| x |
|
(a) |
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
| |
(b) |
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
| |
(c) |
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III - NARRATIVE
State below in reasonable detail why Forms 10-K,
20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
International Stem Cell Corporation (the "Company")
is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the three months ended September 30,
2026 (the “Form 10-Q”) within the prescribed time period. This delay resulted primarily from the disposition of the Company’s
Lifeline Cell Technology business (the “LCT Business”), the closing of which occurred during the third quarter of 2026. In
accordance with Accounting Standards Codification 205-20, Discontinued Operations, the Company is required to present the results of the
LCT Business as a discontinued operation in its condensed consolidated financial statements for the three months ended September 30, 2026.
The accounting treatment requires, among other things, the separation of the LCT Business’s results from continuing operations
for the current period, the retrospective recasting of all prior period comparative financial statements to present the LCT Business as
a discontinued operation, the determination of the gain or loss on disposition, and income taxes between continuing and discontinued operations.
The complexity of this discontinued operations accounting, combined with the need to ensure the accuracy and completeness of the retrospective
recasting of prior periods, has required additional time to complete the Company’s financial close process for the quarter ended
September 30, 2026. The Company has been working diligently to complete the discontinued operations presentation and expects to file the
Form 10-Q on or before the fifth calendar day following the prescribed due date.
PART IV - OTHER INFORMATION
| (1) |
Name and telephone number of person to contact in regard to this notification |
| |
|
|
|
|
|
| |
Russell Kern |
|
|
(760) |
|
|
940-6383 |
| |
(Name) |
|
|
(Area Code) |
|
|
(Telephone Number) |
| |
|
| (2) |
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). x Yes ¨ No |
| |
|
| |
|
| |
|
| (3) |
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ¨ Yes x No |
| |
|
| |
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. |
International Stem Cell Corporation
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
| Date: |
November 17, 2026 |
By: |
/s/ Russell Kern |
| |
|
|
Russell Kern |
| |
|
|
Executive Vice President and Chief Scientific Officer
(Principal Financial Officer) |